[
  {
    "info": {
      "NCT": "NCT05012397",
      "Protocol_No": "3202",
      "jit": "Caris",
      "trial_name": "Rain Therapeutics Inc 3202"
    },
    "disease": {
      "summary": "Advanced or Metastatic Solid Tumors",
      "details": [
        {
          "code": "Solid Tumors",
          "selection": "include"
        }
      ]
    },
    "query": {
      "nct": "NCT05012397",
      "title": "Milademetan in Advanced/Metastatic Solid Tumors",
      "current_status": "Recruiting",
      "status_verif_date": "August 2022",
      "last_update_date": "August 16, 2022",
      "trial_hold_status": "open",
      "sponsor": "Rain Therapeutics Inc.",
      "brief_summary": "Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) â‰¥ 12 using prespecified biomarker criteria.",
      "conditions": "Solid Tumors",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Milademetan (RAIN-32)",
          "drug": "RAIN-32",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Milademetan (RAIN-32)",
              "Gene": "TP53",
              "Gene2": "Not available",
              "Type": "Wild-Type",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "TP53 Wild-Type  "
            },
            {
              "cohort": "Milademetan (RAIN-32)",
              "Gene": "MDM2",
              "Gene2": "Not available",
              "Type": "Amplification",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "MDM2 Amplification  "
            }
          ]
        }
      ],
      "docs": "Q:/MCK/MOA/Precision Oncology/JIT Trials/CarisPharmatechStudyList_2022-07-12.pdf",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT05012397\" target=\"_blank\">NCT05012397<\/a>"
    }
  }
]
